• 340B Program Compliance. Achieve More With Intuitive Solutions.

    It was great to connect with industry leaders during the 15th Annual 340B Coalition Winter Conference! As a pharmacist, clinic director, or C-suite executive, one of your top priorities is to provide safe and cost-effective care and ensure regulatory compliance.   RxStrategies understands the complexities of the 340B program and recognizes the importance of open communication… Read more »

  • Clinical Insights: August 30, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval AltrenoTM (tretinoin) – August 24, 2018 – Ortho Dermatologics, one of the largest prescription dermatology healthcare businesses in the world, announced that the U.S. Food and Drug… Read more »

  • Schedule Your 340B Demos Now!

    The 2018 340B Coalition Summer Conference is just around the corner. July 9-11, we will be in Washington, D.C. as a Pinnacle Leader Sponsor for the conference, ready to connect with you and gain insight into the latest news and trends concerning the 340B Drug Discount Program. If you are attending, be sure to schedule… Read more »

  • Clinical Insights: June 21, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Moxidectin – June 13, 2018 – Medicines Development for Global Health (MDGH) and the World Health Organisation Special Programme for Research and Training in Tropical Diseases… Read more »

  • Clinical Insights: June 4, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Olumiant® (baricitinib) – June 1, 2018 – Eli Lilly and Company and Incyte Corporation announced that the U.S. Food and Drug Administration (FDA) has approved the 2-mg… Read more »

  • Clinical Insights: May 23, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Doptelet® (avatrombopag) – May 21, 2018 – The Food and Drug Administration approved avatrombopag (Doptelet®, AkaRx Inc.) for thrombocytopenia in adults with chronic liver disease scheduled to… Read more »

  • Clinical Insights: May 16, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Retacrit® (epoetin alfa-epbx) – New Biosimilar Drug Approval – May 15, 2018 – U.S. Food and Drug Administration approved Retacrit®(epoetin alfa-epbx) as a biosimilar to Epogen/Procrit (epoetin… Read more »

  • Clinical Insights: May 9, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Plenvu® (polyethylene glycol 3350 with electrolytes) – May 7, 2018 – Salix Pharmaceuticals, Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved Plenvu®… Read more »

  • Clinical Insights: May 1, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval JynarqueTM (tolvaptan) – April 24, 2018 – Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that the U.S. Food and Drug Administration (FDA) has approved JynarqueTM (tolvaptan) as… Read more »

  • Stay on Top of 340B with Split Billing

    RxStrategies recognizes the complexities of 340B program management and offers solutions to better ensure proper management and program compliance. With our Split Billing Solution, you can: Review prescription activity Flag eligible 340B dispenses Designate activity for proper replenishment Audit and report GPO, WAC and 340B With customized reporting, onsite audit support, order confirmations, pharmacy system… Read more »